Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in M&A / Deals

Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions

 April 17, 2026

Pharmaceutical Business Review

The agreement involves Daiichi Sankyo Research Institute Boston and aims to assess the use of Interna’s MNM technology as a delivery enhancer for therapeutic modalities.

M&A / DealsRead full story

Post navigation

Aligos and Xiamen Amoytop sign deal for HBV therapy →
← Multiple myeloma drug Blenrep backed for wider NHS use

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com